SrasV1, 2020, Analysis, bibRecord, 000441

Novel decoy cellular vaccine strategy utilizing transgenic antigen-expressing cells as immune presenter and adjuvant in vaccine prototype against SARS-CoV-2 virus.

Identifieur interne : 000441 ( 2020/Analysis ); précédent : 000440; suivant : 000442

Novel decoy cellular vaccine strategy utilizing transgenic antigen-expressing cells as immune presenter and adjuvant in vaccine prototype against SARS-CoV-2 virus.

Auteurs : Henry Ji [États-Unis] ; Ying Yan [États-Unis] ; Beibei Ding [États-Unis] ; Wenzhong Guo [États-Unis] ; Mark Brunswick [États-Unis] ; Andreas Niethammer [États-Unis] ; Williams Soohoo [États-Unis] ; Robin Smith [États-Unis] ; Alexis Nahama [États-Unis] ; Yanliang Zhang [États-Unis]

Source :

Medicine in drug discovery [ 2590-0986 ] ; 2020.

RBID : pubmed:32289117

Abstract

A novel approach modifying cells to express viral markers to elicit protective immunity responses (decoy cellular vaccination) in the prevention of COVID-19 disease is currently being explored. Our approach entails utilizing SARS-CoV-2 Spike antigen-expressing, non-replicating cells as carriers and presenters of immunogenic antigens, so called "I-cells". By using irradiated cells as presenting vehicles of SARS-CoV-2 viral antigens(s) in a cellular context, these presented viral proteins can be recognized by the host immune system, thus, an efficient protective immune response might be elicited. Another advantage of this strategy is that the manufacturing process is scalable and yields uniform cell products allowing for "off-the-shelf" frozen supply availability. To prevent engraftment and proliferation of the cells after administration, the cells will be irradiated post-harvesting abolishing in vivo replication potential. Specifically, immunoreactive Spike-1 proteins from SARS-CoV-2 are expressed on the surface of irradiated target I-cells. Utilizing this innovative strategy, these viral antigen-displaying decoy cells will be developed as a vaccine to protect against COVID-19 disease.

DOI: 10.1016/j.medidd.2020.100026
PubMed: 32289117

Affiliations:

Links to Exploration step

pubmed:32289117

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Novel decoy cellular vaccine strategy utilizing transgenic antigen-expressing cells as immune presenter and adjuvant in vaccine prototype against SARS-CoV-2 virus.</title>
<author><name sortKey="Ji, Henry" sort="Ji, Henry" uniqKey="Ji H" first="Henry" last="Ji">Henry Ji</name>
<affiliation wicri:level="2"><nlm:affiliation>Sorrento Therapeutics, Inc., 4955 Directors Place, San Diego, CA 92121, United States of America.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Sorrento Therapeutics, Inc., 4955 Directors Place, San Diego, CA 92121</wicri:regionArea>
<placeName><region type="state">Californie</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Yan, Ying" sort="Yan, Ying" uniqKey="Yan Y" first="Ying" last="Yan">Ying Yan</name>
<affiliation wicri:level="2"><nlm:affiliation>Sorrento Therapeutics, Inc., 4955 Directors Place, San Diego, CA 92121, United States of America.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Sorrento Therapeutics, Inc., 4955 Directors Place, San Diego, CA 92121</wicri:regionArea>
<placeName><region type="state">Californie</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Ding, Beibei" sort="Ding, Beibei" uniqKey="Ding B" first="Beibei" last="Ding">Beibei Ding</name>
<affiliation wicri:level="2"><nlm:affiliation>Sorrento Therapeutics, Inc., 4955 Directors Place, San Diego, CA 92121, United States of America.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Sorrento Therapeutics, Inc., 4955 Directors Place, San Diego, CA 92121</wicri:regionArea>
<placeName><region type="state">Californie</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Guo, Wenzhong" sort="Guo, Wenzhong" uniqKey="Guo W" first="Wenzhong" last="Guo">Wenzhong Guo</name>
<affiliation wicri:level="2"><nlm:affiliation>Sorrento Therapeutics, Inc., 4955 Directors Place, San Diego, CA 92121, United States of America.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Sorrento Therapeutics, Inc., 4955 Directors Place, San Diego, CA 92121</wicri:regionArea>
<placeName><region type="state">Californie</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Brunswick, Mark" sort="Brunswick, Mark" uniqKey="Brunswick M" first="Mark" last="Brunswick">Mark Brunswick</name>
<affiliation wicri:level="2"><nlm:affiliation>Sorrento Therapeutics, Inc., 4955 Directors Place, San Diego, CA 92121, United States of America.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Sorrento Therapeutics, Inc., 4955 Directors Place, San Diego, CA 92121</wicri:regionArea>
<placeName><region type="state">Californie</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Niethammer, Andreas" sort="Niethammer, Andreas" uniqKey="Niethammer A" first="Andreas" last="Niethammer">Andreas Niethammer</name>
<affiliation wicri:level="2"><nlm:affiliation>Sorrento Therapeutics, Inc., 4955 Directors Place, San Diego, CA 92121, United States of America.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Sorrento Therapeutics, Inc., 4955 Directors Place, San Diego, CA 92121</wicri:regionArea>
<placeName><region type="state">Californie</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Soohoo, Williams" sort="Soohoo, Williams" uniqKey="Soohoo W" first="Williams" last="Soohoo">Williams Soohoo</name>
<affiliation wicri:level="2"><nlm:affiliation>Sorrento Therapeutics, Inc., 4955 Directors Place, San Diego, CA 92121, United States of America.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Sorrento Therapeutics, Inc., 4955 Directors Place, San Diego, CA 92121</wicri:regionArea>
<placeName><region type="state">Californie</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Smith, Robin" sort="Smith, Robin" uniqKey="Smith R" first="Robin" last="Smith">Robin Smith</name>
<affiliation wicri:level="2"><nlm:affiliation>Sorrento Therapeutics, Inc., 4955 Directors Place, San Diego, CA 92121, United States of America.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Sorrento Therapeutics, Inc., 4955 Directors Place, San Diego, CA 92121</wicri:regionArea>
<placeName><region type="state">Californie</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Nahama, Alexis" sort="Nahama, Alexis" uniqKey="Nahama A" first="Alexis" last="Nahama">Alexis Nahama</name>
<affiliation wicri:level="2"><nlm:affiliation>Sorrento Therapeutics, Inc., 4955 Directors Place, San Diego, CA 92121, United States of America.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Sorrento Therapeutics, Inc., 4955 Directors Place, San Diego, CA 92121</wicri:regionArea>
<placeName><region type="state">Californie</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Zhang, Yanliang" sort="Zhang, Yanliang" uniqKey="Zhang Y" first="Yanliang" last="Zhang">Yanliang Zhang</name>
<affiliation wicri:level="2"><nlm:affiliation>Sorrento Therapeutics, Inc., 4955 Directors Place, San Diego, CA 92121, United States of America.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Sorrento Therapeutics, Inc., 4955 Directors Place, San Diego, CA 92121</wicri:regionArea>
<placeName><region type="state">Californie</region>
</placeName>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2020">2020</date>
<idno type="RBID">pubmed:32289117</idno>
<idno type="pmid">32289117</idno>
<idno type="doi">10.1016/j.medidd.2020.100026</idno>
<idno type="wicri:Area/PubMed/Corpus">000166</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000166</idno>
<idno type="wicri:Area/PubMed/Curation">000166</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000166</idno>
<idno type="wicri:Area/PubMed/Checkpoint">000359</idno>
<idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000359</idno>
<idno type="wicri:Area/Ncbi/Merge">003A19</idno>
<idno type="wicri:Area/Ncbi/Curation">003A19</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">003A19</idno>
<idno type="wicri:Area/Main/Merge">000441</idno>
<idno type="wicri:Area/Main/Curation">000441</idno>
<idno type="wicri:Area/Main/Exploration">000441</idno>
<idno type="wicri:Area/2020/Extraction">000441</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Novel decoy cellular vaccine strategy utilizing transgenic antigen-expressing cells as immune presenter and adjuvant in vaccine prototype against SARS-CoV-2 virus.</title>
<author><name sortKey="Ji, Henry" sort="Ji, Henry" uniqKey="Ji H" first="Henry" last="Ji">Henry Ji</name>
<affiliation wicri:level="2"><nlm:affiliation>Sorrento Therapeutics, Inc., 4955 Directors Place, San Diego, CA 92121, United States of America.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Sorrento Therapeutics, Inc., 4955 Directors Place, San Diego, CA 92121</wicri:regionArea>
<placeName><region type="state">Californie</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Yan, Ying" sort="Yan, Ying" uniqKey="Yan Y" first="Ying" last="Yan">Ying Yan</name>
<affiliation wicri:level="2"><nlm:affiliation>Sorrento Therapeutics, Inc., 4955 Directors Place, San Diego, CA 92121, United States of America.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Sorrento Therapeutics, Inc., 4955 Directors Place, San Diego, CA 92121</wicri:regionArea>
<placeName><region type="state">Californie</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Ding, Beibei" sort="Ding, Beibei" uniqKey="Ding B" first="Beibei" last="Ding">Beibei Ding</name>
<affiliation wicri:level="2"><nlm:affiliation>Sorrento Therapeutics, Inc., 4955 Directors Place, San Diego, CA 92121, United States of America.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Sorrento Therapeutics, Inc., 4955 Directors Place, San Diego, CA 92121</wicri:regionArea>
<placeName><region type="state">Californie</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Guo, Wenzhong" sort="Guo, Wenzhong" uniqKey="Guo W" first="Wenzhong" last="Guo">Wenzhong Guo</name>
<affiliation wicri:level="2"><nlm:affiliation>Sorrento Therapeutics, Inc., 4955 Directors Place, San Diego, CA 92121, United States of America.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Sorrento Therapeutics, Inc., 4955 Directors Place, San Diego, CA 92121</wicri:regionArea>
<placeName><region type="state">Californie</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Brunswick, Mark" sort="Brunswick, Mark" uniqKey="Brunswick M" first="Mark" last="Brunswick">Mark Brunswick</name>
<affiliation wicri:level="2"><nlm:affiliation>Sorrento Therapeutics, Inc., 4955 Directors Place, San Diego, CA 92121, United States of America.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Sorrento Therapeutics, Inc., 4955 Directors Place, San Diego, CA 92121</wicri:regionArea>
<placeName><region type="state">Californie</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Niethammer, Andreas" sort="Niethammer, Andreas" uniqKey="Niethammer A" first="Andreas" last="Niethammer">Andreas Niethammer</name>
<affiliation wicri:level="2"><nlm:affiliation>Sorrento Therapeutics, Inc., 4955 Directors Place, San Diego, CA 92121, United States of America.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Sorrento Therapeutics, Inc., 4955 Directors Place, San Diego, CA 92121</wicri:regionArea>
<placeName><region type="state">Californie</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Soohoo, Williams" sort="Soohoo, Williams" uniqKey="Soohoo W" first="Williams" last="Soohoo">Williams Soohoo</name>
<affiliation wicri:level="2"><nlm:affiliation>Sorrento Therapeutics, Inc., 4955 Directors Place, San Diego, CA 92121, United States of America.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Sorrento Therapeutics, Inc., 4955 Directors Place, San Diego, CA 92121</wicri:regionArea>
<placeName><region type="state">Californie</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Smith, Robin" sort="Smith, Robin" uniqKey="Smith R" first="Robin" last="Smith">Robin Smith</name>
<affiliation wicri:level="2"><nlm:affiliation>Sorrento Therapeutics, Inc., 4955 Directors Place, San Diego, CA 92121, United States of America.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Sorrento Therapeutics, Inc., 4955 Directors Place, San Diego, CA 92121</wicri:regionArea>
<placeName><region type="state">Californie</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Nahama, Alexis" sort="Nahama, Alexis" uniqKey="Nahama A" first="Alexis" last="Nahama">Alexis Nahama</name>
<affiliation wicri:level="2"><nlm:affiliation>Sorrento Therapeutics, Inc., 4955 Directors Place, San Diego, CA 92121, United States of America.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Sorrento Therapeutics, Inc., 4955 Directors Place, San Diego, CA 92121</wicri:regionArea>
<placeName><region type="state">Californie</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Zhang, Yanliang" sort="Zhang, Yanliang" uniqKey="Zhang Y" first="Yanliang" last="Zhang">Yanliang Zhang</name>
<affiliation wicri:level="2"><nlm:affiliation>Sorrento Therapeutics, Inc., 4955 Directors Place, San Diego, CA 92121, United States of America.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Sorrento Therapeutics, Inc., 4955 Directors Place, San Diego, CA 92121</wicri:regionArea>
<placeName><region type="state">Californie</region>
</placeName>
</affiliation>
</author>
</analytic>
<series><title level="j">Medicine in drug discovery</title>
<idno type="eISSN">2590-0986</idno>
<imprint><date when="2020" type="published">2020</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass></textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">A novel approach modifying cells to express viral markers to elicit protective immunity responses (decoy cellular vaccination) in the prevention of COVID-19 disease is currently being explored. Our approach entails utilizing SARS-CoV-2 Spike antigen-expressing, non-replicating cells as carriers and presenters of immunogenic antigens, so called "I-cells". By using irradiated cells as presenting vehicles of SARS-CoV-2 viral antigens(s) in a cellular context, these presented viral proteins can be recognized by the host immune system, thus, an efficient protective immune response might be elicited. Another advantage of this strategy is that the manufacturing process is scalable and yields uniform cell products allowing for "off-the-shelf" frozen supply availability. To prevent engraftment and proliferation of the cells after administration, the cells will be irradiated post-harvesting abolishing in vivo replication potential. Specifically, immunoreactive Spike-1 proteins from SARS-CoV-2 are expressed on the surface of irradiated target I-cells. Utilizing this innovative strategy, these viral antigen-displaying decoy cells will be developed as a vaccine to protect against COVID-19 disease.</div>
</front>
</TEI>
<affiliations><list><country><li>États-Unis</li>
</country>
<region><li>Californie</li>
</region>
</list>
<tree><country name="États-Unis"><region name="Californie"><name sortKey="Ji, Henry" sort="Ji, Henry" uniqKey="Ji H" first="Henry" last="Ji">Henry Ji</name>
</region>
<name sortKey="Brunswick, Mark" sort="Brunswick, Mark" uniqKey="Brunswick M" first="Mark" last="Brunswick">Mark Brunswick</name>
<name sortKey="Ding, Beibei" sort="Ding, Beibei" uniqKey="Ding B" first="Beibei" last="Ding">Beibei Ding</name>
<name sortKey="Guo, Wenzhong" sort="Guo, Wenzhong" uniqKey="Guo W" first="Wenzhong" last="Guo">Wenzhong Guo</name>
<name sortKey="Nahama, Alexis" sort="Nahama, Alexis" uniqKey="Nahama A" first="Alexis" last="Nahama">Alexis Nahama</name>
<name sortKey="Niethammer, Andreas" sort="Niethammer, Andreas" uniqKey="Niethammer A" first="Andreas" last="Niethammer">Andreas Niethammer</name>
<name sortKey="Smith, Robin" sort="Smith, Robin" uniqKey="Smith R" first="Robin" last="Smith">Robin Smith</name>
<name sortKey="Soohoo, Williams" sort="Soohoo, Williams" uniqKey="Soohoo W" first="Williams" last="Soohoo">Williams Soohoo</name>
<name sortKey="Yan, Ying" sort="Yan, Ying" uniqKey="Yan Y" first="Ying" last="Yan">Ying Yan</name>
<name sortKey="Zhang, Yanliang" sort="Zhang, Yanliang" uniqKey="Zhang Y" first="Yanliang" last="Zhang">Yanliang Zhang</name>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/SrasV1/Data/2020/Analysis

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000441 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/2020/Analysis/biblio.hfd -nk 000441 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    SrasV1
   |flux=    2020
   |étape=   Analysis
   |type=    RBID
   |clé=     pubmed:32289117
   |texte=   Novel decoy cellular vaccine strategy utilizing transgenic antigen-expressing cells as immune presenter and adjuvant in vaccine prototype against SARS-CoV-2 virus.
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/2020/Analysis/RBID.i   -Sk "pubmed:32289117" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/2020/Analysis/biblio.hfd   \
       | NlmPubMed2Wicri -a SrasV1

This area was generated with Dilib version V0.6.33.
Data generation: Tue Apr 28 14:49:16 2020. Site generation: Sat Mar 27 22:06:49 2021

Serveur d'exploration SRAS

Novel decoy cellular vaccine strategy utilizing transgenic antigen-expressing cells as immune presenter and adjuvant in vaccine prototype against SARS-CoV-2 virus.

Novel decoy cellular vaccine strategy utilizing transgenic antigen-expressing cells as immune presenter and adjuvant in vaccine prototype against SARS-CoV-2 virus.

Source :

Abstract

Links toward previous steps (curation, corpus...)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

Pour générer des pages wiki

	Serveur d'exploration SRAS
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.